JP7820152B2 - キナーゼ依存性障害の処置のための化合物 - Google Patents
キナーゼ依存性障害の処置のための化合物Info
- Publication number
- JP7820152B2 JP7820152B2 JP2021571941A JP2021571941A JP7820152B2 JP 7820152 B2 JP7820152 B2 JP 7820152B2 JP 2021571941 A JP2021571941 A JP 2021571941A JP 2021571941 A JP2021571941 A JP 2021571941A JP 7820152 B2 JP7820152 B2 JP 7820152B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclopropane
- dicarboxamide
- fluorophenyl
- oxyphenyl
- quinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856920P | 2019-06-04 | 2019-06-04 | |
| US62/856,920 | 2019-06-04 | ||
| PCT/US2020/035808 WO2020247418A1 (en) | 2019-06-04 | 2020-06-03 | Compounds for the treatment of kinase-dependent disorders |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022535108A JP2022535108A (ja) | 2022-08-04 |
| JP2022535108A5 JP2022535108A5 (https=) | 2023-06-12 |
| JPWO2020247418A5 JPWO2020247418A5 (https=) | 2023-06-12 |
| JP7820152B2 true JP7820152B2 (ja) | 2026-02-25 |
Family
ID=71842789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571941A Active JP7820152B2 (ja) | 2019-06-04 | 2020-06-03 | キナーゼ依存性障害の処置のための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12503438B2 (https=) |
| EP (1) | EP3980404A1 (https=) |
| JP (1) | JP7820152B2 (https=) |
| CN (1) | CN114040912B (https=) |
| AR (1) | AR119069A1 (https=) |
| AU (1) | AU2020289324B2 (https=) |
| CA (1) | CA3139156A1 (https=) |
| MA (1) | MA56114A (https=) |
| TW (1) | TWI850394B (https=) |
| WO (1) | WO2020247418A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| CN114573553B (zh) * | 2022-01-27 | 2023-11-10 | 广州六顺生物科技有限公司 | 杂芳环类衍生物及其制备方法和应用 |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
| CN116271008A (zh) * | 2022-12-30 | 2023-06-23 | 广东天普生化医药股份有限公司 | 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007506777A (ja) | 2003-09-26 | 2007-03-22 | エグゼリクシス， インコーポレイテッド | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2009526761A (ja) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| CN104817497A (zh) | 2015-03-20 | 2015-08-05 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| WO2018049861A1 (zh) | 2016-09-13 | 2018-03-22 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| JP2018520109A (ja) | 2015-05-21 | 2018-07-26 | 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | ピリド−アザヘテロサイクリック化合物及びその製造方法と用途 |
| JP2021506885A (ja) | 2017-12-20 | 2021-02-22 | エンジェクス ファーマシューティカル インコーポレイテッド | マルチキナーゼ阻害剤としてのカルバメートおよび尿素化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| IL248408B (en) * | 2014-04-25 | 2022-06-01 | Exelixis Inc | A method for treating adenocarcinoma of the lungs |
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
-
2020
- 2020-06-02 AR ARP200101554A patent/AR119069A1/es unknown
- 2020-06-03 AU AU2020289324A patent/AU2020289324B2/en active Active
- 2020-06-03 MA MA056114A patent/MA56114A/fr unknown
- 2020-06-03 US US17/616,120 patent/US12503438B2/en active Active
- 2020-06-03 JP JP2021571941A patent/JP7820152B2/ja active Active
- 2020-06-03 EP EP20747207.7A patent/EP3980404A1/en active Pending
- 2020-06-03 CN CN202080048050.0A patent/CN114040912B/zh active Active
- 2020-06-03 CA CA3139156A patent/CA3139156A1/en active Pending
- 2020-06-03 WO PCT/US2020/035808 patent/WO2020247418A1/en not_active Ceased
- 2020-06-04 TW TW109118785A patent/TWI850394B/zh active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007506777A (ja) | 2003-09-26 | 2007-03-22 | エグゼリクシス， インコーポレイテッド | ｃ−Ｍｅｔモジュレーターおよびその使用 |
| JP2009526761A (ja) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| CN104817497A (zh) | 2015-03-20 | 2015-08-05 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| JP2018520109A (ja) | 2015-05-21 | 2018-07-26 | 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | ピリド−アザヘテロサイクリック化合物及びその製造方法と用途 |
| WO2018049861A1 (zh) | 2016-09-13 | 2018-03-22 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| JP2021506885A (ja) | 2017-12-20 | 2021-02-22 | エンジェクス ファーマシューティカル インコーポレイテッド | マルチキナーゼ阻害剤としてのカルバメートおよび尿素化合物 |
Non-Patent Citations (1)
| Title |
|---|
| S. D. Modi et al. ，3D-QSAR analysis of pyrimidine derivatives as AXL kinase inhibitors as anticancer agents，JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE，2018年，8(11)，pp. 15-27 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022535108A (ja) | 2022-08-04 |
| US20230043835A1 (en) | 2023-02-09 |
| TW202110806A (zh) | 2021-03-16 |
| AU2020289324A1 (en) | 2021-12-16 |
| CA3139156A1 (en) | 2020-12-10 |
| US12503438B2 (en) | 2025-12-23 |
| MA56114A (fr) | 2022-04-13 |
| AU2020289324B2 (en) | 2026-04-23 |
| AR119069A1 (es) | 2021-11-24 |
| EP3980404A1 (en) | 2022-04-13 |
| CN114040912A (zh) | 2022-02-11 |
| TWI850394B (zh) | 2024-08-01 |
| WO2020247418A1 (en) | 2020-12-10 |
| CN114040912B (zh) | 2024-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690517B2 (ja) | キナーゼ依存的障害を処置するための化合物 | |
| US12195475B2 (en) | Compounds for the treatment of kinase-dependent disorders | |
| JP7820152B2 (ja) | キナーゼ依存性障害の処置のための化合物 | |
| US11673897B2 (en) | Compounds for the treatment of kinase-dependent disorders | |
| HK40068336A (en) | Compounds for the treatment of kinase-dependent disorders | |
| HK40068336B (zh) | 用於治疗激酶依赖性病症的化合物 | |
| BR112020015199B1 (pt) | Composto, composição farmacêutica e uso dos mesmos para tratar distúrbios dependentes de quinase | |
| HK40039571A (en) | Compounds for the treatment of kinase-dependent disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230602 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240531 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250310 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251010 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260114 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7820152 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |